Advocacy intelligence hub — real-time data for patient organizations
Krintafel: FDA approved
KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Spondyloepiphyseal dysplasia-brachydactyly-speech disorder syndrome news →
View all Spondyloepiphyseal dysplasia-brachydactyly-speech disorder syndrome specialists →